Cenobamate in Adults With Focal-Onset Seizures

Inclusion Criteria:

• Age ≥18 years at the time of cenobamate treatment initiation
• Male or female patients
• Patients diagnosed with focal epilepsy uncontrolled despite a history of treatmentwith at least two antiepileptic medicinal products at the time of cenobamate treatmentinitiation in agreement with the Summary of Product Characteristics (SmPC)
• Patients who at enrolment had received at least 12 weeks (titration period up to theinitial recommended target dose of 200 mg daily completed) but no more than 52 weeksof cenobamate as adjunctive treatment of focal-onset seizures with or withoutsecondary generalization
• Patients with available retrospective data in medical charts and seizure diaries,including information about baseline seizure frequency prior to cenobamate treatmentinitiation
• Patients who gave written informed consent to take part into the study and personaldata processing consent following local regulation.
• Patients who received adjunctive cenobamate for at least 12 weeks and discontinuedpermanently treatment before enrolment will also be included in the study-

Exclusion Criteria:

• Patients diagnosed with familial short-QT syndrome
• Patients affected by hypersensitivity to the active substance cenobamate or to any ofthe excipients (e.g., lactose monohydrate)
• Patients with history of severe drug-induced hypersensitivity reaction, including (butnot limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), andStevens Johnson syndrome
• Patients enrolled in a clinical trial in which treatments for epilepsy are managedthrough a study protocol
• Patient unable to read and write in Italian language and to autonomously fill inquestionnaires and scales
• Patients with a known pregnancy or who are breast-feeding from cenobamate treatmentinitiation till enrolment visit.